Small interfering RNAs (siRNAs) indicate the unprecedented versatility in silencing disease-causing genes. However, the therapeutic use of siRNA is limited by its inherent instability in serum and immunogenicity. Thus, to realize their full therapeutic potential, there is a growing need to develop an efficient siRNA delivery system that targets it towards the localized symptomatic sites. Consequently, nanosized lipid carriers have been utilized for the targeted delivery of therapeutic agents to improve their efficacy in clinical studies. In this review, we attempt to elaborate on the current improvements of chemically diverse lipid carriers for the delivery of siRNAs-based drugs across a wide range of diseases. Finally, we discuss the patents and clinical status of siRNA in lipid formulations, which continue to expand for years to come.

中文翻译：

---

基于脂质的纳米载体，可用于治疗用途的小干扰RNA的输送。

小型干扰RNA（siRNA）表明，在沉默致病基因方面具有前所未有的多功能性。但是，siRNA的治疗用途受到其固有的血清不稳定性和免疫原性的限制。因此，为了实现其全部治疗潜力，越来越需要开发一种有效的siRNA递送系统，将其靶向局部症状部位。因此，纳米脂质载体已被用于靶向递送治疗剂以改善其在临床研究中的功效。在这篇综述中，我们试图详细阐述化学上多样化的脂质载体的当前改进，以用于在多种疾病中递送基于siRNA的药物。最后，我们讨论了脂质制剂中siRNA的专利和临床状况，这些专利在未来几年中会不断扩展。